Bausch Health reports Q1 non-GAAP EPS 78c, consensus 69c

Reports Q1 revenue $2.52B, consensus $2.41B. “Our Q1 performance marks twelve consecutive periods of year-over-year growth in revenue, adjusted EBITDA for Bausch Health (BHC) excluding Bausch + Lomb, reflecting strategic execution and disciplined accountability across our organization. We continue to invest in our pipeline, including the advancement of larsucosterol to treat alcohol-associated hepatitis, while pursuing business development opportunities aligned with our strategic priorities. With this momentum, we reaffirm our full-year 2026 outlook and remain focused on driving sustainable performance and shareholder value,” said CEO Thomas Appio.